Xia Jin,
Mark J Newman,
Stephen De-Rosa,
Cristine Cooper, Evan Thomas,
Michael Keefer,
Jonathan Fuchs,
William Blattner,
Brian D Livingston,
Denise M McKinney,
Elizabeth Noonan,
Allan Decamp,
Olivier D Defawe,
Margaret Wecker
[show abstract]
[hide abstract]
ABSTRACT: A Phase I human vaccine trial of a novel polypeptide vaccine of HIV T helper epitopes (EP-1043) and a DNA vaccine of HIV CTL epitopes was conducted in 84 healthy adult volunteers. The vaccine immunogenicity was assessed by an intracellular cytokine staining assay for IL-2, IL-4, TNF-alpha and IFN-gamma. Sixty eight percent (32/47) of subjects had a positive CD4+ T response after receiving two vaccinations of the polypeptide vaccine. The responding CD4+ T cells made various combinations of IL-2, IL-4, IFN-gamma, and TNF-alpha. The study demonstrated that the EP-1043 vaccine is safe, well-tolerated, and immunogenic.
Vaccine 09/2009; 27(50):7080-6. · 3.77 Impact Factor
